Expansion of a Population of Large Monocytes (Atypical Monocytes) in Peripheral Blood of Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Diseases
Table 2
Surface marker expression of A Mo and T Mo from AECOPD patients and controls.
%
MFI
Healthy
AECOPD
Remission
Healthy
AECOPD
Remission
T Mo
T Mo
A Mo
T Mo
A Mo
T Mo
T Mo
A Mo
T Mo
A Mo
CD14
92.79 ± 2.09
97.47 ± 1.45
96.66 ± 2.06
98.28 ± 0.81
96.88 ± 2.04
607.00 ± 84.73
441.68 ± 115.60
551.59 ± 149.01
441.41 ± 93.74
521.47 ± 120.94
CD16
13.84 ± 4.83
13.14 ± 11.36
18.76 ± 12.62
8.43 ± 7.14
16.10 ± 9.80
8.21 ± 4.16
8.81 ± 5.07
12.74 ± 7.07
6.41 ± 2.06
10.53 ± 4.49
HLA-DR
83.69 ± 8.95
49.27 ± 12.65
66.42 ± 17.92
54.05 ± 25.26
69.83 ± 22.82
53.71 ± 22.13
28.82 ± 10.25
53.44 ± 29.25
39.73 ± 25.32
65.46 ± 39.66
ICAM-1
23.84 ± 4.65
25.14 ± 17.52
33.19 ± 19.44
26.75 ± 12.16
36.84 ± 12.83
21.53 ± 2.89
28.20 ± 8.51
34.59 ± 12.34
31.53 ± 6.92
39.59 ± 8.63
CCR2
94.69 ± 1.40
96.19 ± 2.67
95.27 ± 3.35
97.08 ± 2.10
95.30 ± 4.18
252.63 ± 32.97
292.00 ± 75.13
327.68 ± 96.90
307.47 ± 76.62
339.41 ± 81.98
Data are expressed as the mean ± SD, and Student’s t-test and a nonparametric Newman-Keuls test were used for comparisons between groups. ,, and versus healthy.
